| A Clinical Study to Evaluate Single-agent Therapy of BR113 for Injection in Patients With Advanced Solid Tumors (NCT07753590) | BioRay Pharmaceutical Co., Ltd. | 2026-08-01 |
| Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia (NCT07498647) | BioRay Pharmaceutical Co., Ltd. | 2026-04-01 |
| Phase IIa Study of BRY812 Monotherapy in Advanced Gynecological Malignancies (NCT07311538) | BioRay Pharmaceutical Co., Ltd. | 2025-12-01 |
| A Study of BR111 in Patients With Advanced Malignancies (NCT06937957) | BioRay Pharmaceutical Co., Ltd. | 2025-04-24 |
| A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy (NCT06642909) | BioRay Pharmaceutical Co., Ltd. | 2024-11-13 |
| A Study of BRY805 in Participants With Advanced Solid Tumors (NCT06289894) | BioRay Pharmaceutical Co., Ltd. | 2024-03-13 |
| A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies (NCT06388902) | BioRay Pharmaceutical Co., Ltd. | 2024-02-19 |
| A Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies (NCT06038058) | BioRay Pharmaceutical Co., Ltd. | 2023-10-10 |
| Phase I/II Clinical Study of 1A46 Drug Substance (NCT05987605) | BioRay Pharmaceutical Co., Ltd. | 2023-09-12 |
| A Phase I Study of BR108 in Hematological Malignancies (NCT06018506) | BioRay Pharmaceutical Co., Ltd. | 2023-03-18 |
| Clinical Study of BR105 Injection (NCT05351697) | BioRay Pharmaceutical Co., Ltd. | 2022-04-19 |
| Comparison of Pharmacokinetics and Safety of HS627(2 Specifications) Versus PERJETA With a Single Injection (NCT05323981) | BioRay Pharmaceutical Co., Ltd. | 2022-04-11 |
| A Study of BR101 Injection Alone in Subjects With Advanced Solid Tumors (NCT06001580) | BioRay Pharmaceutical Co., Ltd. | 2021-08-11 |
| Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel (NCT04514419) | BioRay Pharmaceutical Co., Ltd. | 2020-06-28 |